Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 18, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.
Trial Details
NCT Number NCT07179653
Lead Sponsor Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Collaborators: Nanfang Hospital, Southern Medical University, Sichuan Provincial People's Hospital, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Ruijin Hospital
Conditions HBV Infection
Enrollment 48 participants
Start Date 2025-01-22
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-18